EA200600622A1 - MEANS, possessing antiviral activity, and the method of its production - Google Patents

MEANS, possessing antiviral activity, and the method of its production

Info

Publication number
EA200600622A1
EA200600622A1 EA200600622A EA200600622A EA200600622A1 EA 200600622 A1 EA200600622 A1 EA 200600622A1 EA 200600622 A EA200600622 A EA 200600622A EA 200600622 A EA200600622 A EA 200600622A EA 200600622 A1 EA200600622 A1 EA 200600622A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rimantadine
sodium alginate
antiviral activity
temperature
complex
Prior art date
Application number
EA200600622A
Other languages
Russian (ru)
Other versions
EA007919B1 (en
Inventor
Михаил Константинович Кузьмич
Лев Михайлович Прутков
Original Assignee
Закрытое Акционерное Общество "Вега Фарм"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Закрытое Акционерное Общество "Вега Фарм" filed Critical Закрытое Акционерное Общество "Вега Фарм"
Priority to EA200600622A priority Critical patent/EA200600622A1/en
Publication of EA007919B1 publication Critical patent/EA007919B1/en
Publication of EA200600622A1 publication Critical patent/EA200600622A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к медицине, более точно к фармацевтической промышленности, и может быть использовано в промышленной технологии производства препарата для профилактики и лечения вирусных заболеваний различной этиологии. Способ получения средства, обладающего противовирусной активностью, на основе комплекса римантадина и альгината натрия, заключается в том, что римантадин растворяют при температуре 55-65°С в воде, затем в охлажденный до 15-35°С раствор вводят низкомолекулярный альгинат натрия (вязкость 1% раствора в воде 9-26 мПа∙с) при условии, что массовое соотношение римантадин - альгинат натрия составляет (0,56-0,64):1, оставляют набухать в течение 5-10 ч, а затем диспергируют при температуре 15-35°С в течение 30-60 мин высокоскоростной мешалкой до образования стабильного коллоидного раствора солевого комплекса с последующим введением его при температуре 60-80°С в раствор сахара, окрашенный с помощью пищевого красителя. Средство, обладающее противовирусной активностью, на основе комплекса римантадина и альгината натрия получено заявленным способом и содержит исходные компоненты в 100 мл препарата в следующем соотношении, г:The invention relates to medicine, more specifically to the pharmaceutical industry, and can be used in industrial production technology of the drug for the prevention and treatment of viral diseases of various etiologies. The method of obtaining an agent with antiviral activity, based on a complex of rimantadine and sodium alginate, is that rimantadine is dissolved at a temperature of 55-65 ° C in water, then low-molecular-weight sodium alginate (viscosity 1 % solution in water 9-26 MPa ∙ s) provided that the mass ratio of rimantadine - sodium alginate is (0.56-0.64): 1, is left to swell for 5-10 hours, and then dispersed at a temperature of 15- 35 ° C for 30-60 minutes with a high-speed mixer until stable colloidal solution of a complex salt, followed by introducing it at a temperature of 60-80 ° C in a solution of sugar, colored by a food dye. The tool with antiviral activity, based on the complex of rimantadine and sodium alginate obtained by the claimed method and contains the original components in 100 ml of the drug in the following ratio, g:

EA200600622A 2006-04-19 2006-04-19 MEANS, possessing antiviral activity, and the method of its production EA200600622A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA200600622A EA200600622A1 (en) 2006-04-19 2006-04-19 MEANS, possessing antiviral activity, and the method of its production

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA200600622A EA200600622A1 (en) 2006-04-19 2006-04-19 MEANS, possessing antiviral activity, and the method of its production

Publications (2)

Publication Number Publication Date
EA007919B1 EA007919B1 (en) 2007-02-27
EA200600622A1 true EA200600622A1 (en) 2007-02-27

Family

ID=42121397

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600622A EA200600622A1 (en) 2006-04-19 2006-04-19 MEANS, possessing antiviral activity, and the method of its production

Country Status (1)

Country Link
EA (1) EA200600622A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443410C1 (en) * 2011-01-19 2012-02-27 Михаил Константинович Кузьмич Method for preparing antiviral agents (versions)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2381807C1 (en) * 2008-07-18 2010-02-20 Алексей Глебович Одинец Antiviral agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01197437A (en) * 1988-01-29 1989-08-09 Dso Pharmachim Antiviral agent
EP0324875A1 (en) * 1988-01-20 1989-07-26 S O "Pharmachim" Anti-virus drug
RU2185822C2 (en) * 2000-08-01 2002-07-27 Общество с ограниченной ответственностью "Фармаген" Preparation for treatment and prophylaxis of viral diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2443410C1 (en) * 2011-01-19 2012-02-27 Михаил Константинович Кузьмич Method for preparing antiviral agents (versions)

Also Published As

Publication number Publication date
EA007919B1 (en) 2007-02-27

Similar Documents

Publication Publication Date Title
NO20081212L (en) Xanthine derivatives as selective HM74A agonists
EA201001287A1 (en) TREATMENT OF HYPERGLYCEMIA 25-HYDROXIVITAMIN D3
BRPI0509217A8 (en) alginate oligosaccharide and its derivatives, their preparation and their uses
AR042705A1 (en) DERIVATIVES OF PIRAZOL PPAR MODULATOR
EA201201281A1 (en) ENHANCEMENT OF DIETS OF MOTHERS WITH SIAL ACID
BR112018010861A2 (en) foundry mass and process for manufacturing gelatin products
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
EA200600622A1 (en) MEANS, possessing antiviral activity, and the method of its production
IT201800010393A1 (en) Food supplement designed to reduce the release of inflammatory agents and their use
EA201600364A1 (en) 2-METHYLSULFANIL-6-NITRO-7-OXO-1,2,4-TRIAZOLO [5,1-C] [1,2,4] TRIAZINID L-ARGININIA DIHYDRATE, HAVING ACTIVITY, METHOD FOR ITS PREPARATION AND APPLICATION OF PREVENTION AND PREVENTION WESTERN NEIL FEVER
CN103919761B (en) A kind of phenylalanine sequestration calcium powder and processing method
Scordino et al. Anti-apoptotic and anti-inflammatory properties of grapefruit IntegroPectin on human microglial HMC3 cell line
CN103125829A (en) Blood-glucose-lowering noodle making method
CN104068013B (en) A kind of sheep sperm dilution conserving liquid and preparation method thereof
CN102988404B (en) Astragalus polysaccharide injection and preparation method thereof
AR104371A1 (en) PROCEDURE FOR THE PREPARATION OF A COMPOSITION THAT INCLUDES PROTEIN FIBERS
CN112841089A (en) Preparation method of zebra fish thrombus model
CN103860507B (en) A kind of dihydroergotoxine methanesulfonate sustained release tablets and preparation method thereof
RU2741948C1 (en) Method for preventing hypercoagulation in animals under stress
BRPI0517004A (en) food product containing one or more living microorganisms and at least one bioactive food ingredient of interest, the preparation process thereof and uses of a food product and at least one bait food ingredient
CN108260798A (en) A kind of content health table salt and preparation method thereof
RU2011108631A (en) METHOD FOR PREVENTION OF INTESTINAL INTESTINOSIS INCONSISTENCY
Oliveira et al. Effects of phenylalanine on reproductive performance and teratogenesis in mice
ZHONG et al. Study on the anti-inflammatory activity of chaga mushroom aqueous extract-alcohol precipitate
CN105055373A (en) Preparation of embedded lutein ester

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ KG TJ

PC4A Registration of transfer of a eurasian patent by assignment
QZ4A Registered corrections and amendments in a licence
PC4A Registration of transfer of a eurasian patent by assignment
QB4A Registration of a licence in a contracting state
QZ4A Registered corrections and amendments in a licence
QC4A Termination of a registered licence in a contracting state
QB4A Registration of a licence in a contracting state
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
TC4A Change in name of a patent proprietor in a eurasian patent